This guidance replaces NICE technology appraisal guidance 110 issued in September 2006. For details see 'About this guidance'.
1.1 Rituximab, in combination with:
cyclophosphamide, vincristine and prednisolone (CVP)
cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)
mitoxantrone, chlorambucil and prednisolone (MCP)
cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-α (CHVPi) or
is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated people.